Benzodiazepine Use and Risk of Acute Angle-Closure Glaucoma: A Population-Based Case-Crossover Study

Woo Jung Kim, Junqing Li, In-Sun Oh, Inmyung Song, Eun Lee, Kee Namkoong and Ju-Young Shin ()
Additional contact information
Woo Jung Kim: Yongin Severance Hospital, Yonsei University College of Medicine
Junqing Li: Sungkyunkwan University
In-Sun Oh: Sungkyunkwan University
Inmyung Song: Kongju National University College of Nursing and Health
Eun Lee: Institute of Behavioral Science in Medicine, Yonsei University College of Medicine
Kee Namkoong: Institute of Behavioral Science in Medicine, Yonsei University College of Medicine
Ju-Young Shin: Sungkyunkwan University

Drug Safety, 2020, vol. 43, issue 6, No 5, 539-547

Abstract: Abstract Introduction Theoretically, benzodiazepines (BZDs) can narrow the iridocorneal angle and induce acute angle-closure glaucoma (AACG). However, little evidence exists regarding this association. Objective The objective of this study was to assess whether the use of BZDs is associated with the risk of AACG. Methods We conducted a population-based case-crossover study using the nationwide claims database of the National Health Insurance Service in Korea. Patients with newly diagnosed AACG—between 1 January 2013 and 31 December 2016—who had received at least one BZD prescription prior to AACG diagnosis were enrolled. The date of AACG diagnosis was set as the index date. We assessed BZD use by each patient during a 30-day case period prior to the index date and three consecutive control periods that preceded this date. We used conditional logistic regression that adjusted for concomitant medications to determine the odds ratio for the use of BZDs in the case period compared with that in the control period in patients with incident AACG. Results Of the 11,093 patients with incident AACG, 6709 received a prescription for BZD prior to diagnosis. BZD use was associated with an increased risk of AACG [adjusted odds ratio (aOR) = 1.40; 95% confidence interval (CI) 1.27–1.54]. AACG risk was similar for short-acting (aOR = 1.40, 95% CI 1.24–1.57) and long-acting BZDs (aOR = 1.33, 95% CI 1.18–1.50). Conclusion We found that BZD use was associated with AACG risk in the Korean population. Clinicians should carefully monitor the occurrence of visual disturbance in BZD-treated patients.

Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-00914-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:43:y:2020:i:6:d:10.1007_s40264-020-00914-7

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-00914-7

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().